Physician profile
Sharon A Winter
NPI 1255518411
$6,611.89
in general payments reported to CMS, 2019-2025
34 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $473 · 2023: $2,181 · 2024: $2,742 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,138.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $920.08 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $905.79 | 2022-2025 | |
| Pfizer INC. | $694.44 | 2023-2025 | |
| Corium, LLC | $692.47 | 2022-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $485.69 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $415.85 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $286.65 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.22 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $246.36 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.06 | 2022-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $201.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $148.70 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $144.83 | 2022-2025 | Vivitrol, Vivitrol |
| Phathom Pharmaceuticals, INC. | $132.24 | 2024-2025 | Voquezna |
| Tris Pharma INC | $116.15 | 2023-2024 | Dyanavel Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $81.77 | 2023-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $77.01 | 2023-2024 | Xarelto |
| Abbott Laboratories | $75.38 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Almatica Pharma LLC | $74.16 | 2023-2025 | Loreev Xr, Gralise |
| Tolmar, INC. | $58.47 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $53.06 | 2023-2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $43.52 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.41 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $31.39 | 2023 | Quviviq |
| Kyowa Kirin, INC. | $29.28 | 2024 | Crysvita |
| Amgen INC. | $28.45 | 2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $24.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.69 | 2024 | |
| Inspire Medical Systems, INC. | $21.55 | 2024 | Inspire |
| Hologic Sales and Service, LLC | $20.49 | 2023 | Thinprep 2000 Processor, Aptima |
| Neos Therapeutics, LP | $18.62 | 2022 | |
| Ardelyx, INC. | $16.81 | 2023 | Ibsrela |
| Sanofi Pasteur INC. | $14.68 | 2022 | |
| Currax Pharmaceuticals LLC | $13.93 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.